Compare Abbott Laboratories (ABT) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Mercadolibre Inc — how do they compare? Abbott Laboratories trades at $110.98 (market cap $187.95B), while Mercadolibre Inc trades at $1,875.48 (market cap $98.35B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.32% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| ABT | MELI | |
|---|---|---|
Market Cap | $187.95B | $98.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $2.51K |
52-Week Low | $82.57 | $1.55K |
Enterprise Value | $214.96B | $106.00B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
MercadoLibre (MELI) trades at $1,824.34, up 0.2% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $9.19, beating estimates by 6.2%, while revenue grew 50% year-over-year. Operating cash flow reached $12.12 billion in 2025, supporting aggressive growth investments. Analyst consensus remains strongly bullish with a $2,150 price target, though margin compression from strategic spending presents near-term headwinds.
MELI's growth-first strategy drives market share gains but pressures profitability, with net margin declining to 5.3%. The stock offers 18% upside to consensus target but faces execution risk in balancing expansion with returns. Competitive threats from global e-commerce players and Latin American economic volatility require monitoring. Long-term prospects remain positive given ecosystem strength and dominant market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
